Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

blank

 

Recent News and Articles on the Keywords: novel therapeutic + therapeutic strategy + inhibition  Related to the article below (Last Update: 5/5/2008)


Nature.com (subscription)
Spice might protect the heart
Nature.com (subscription), UK - May 2, 2008
Addressing such issues, together with further studies to better understand the effects of curcumin, might lead to the development of novel therapeutic ...
Fox Chase Team Uses Murine Cell Assay to Find Novel Kinase Inhibitor
Cell Based Assay News (subscription), NY - Apr 25, 2008
We are now using this compound to determine whether inhibition of Pak is a viable therapeutic strategy for treating these diseases. By taking, for example, ...
Metabasis Therapeutics Announces First Quarter 2008 Results and ...
WELT ONLINE, Germany - May 1, 2008
These results support our belief that FBPase inhibition could be an important new therapeutic approach for patients suffering with this debilitating disease ...MBRX
Identification of novel vascular markers through gene expression ...
7thSpace Interactive (press release), NY - Apr 30, 2008
Targeting tumor angiogenesis and vasculature is a promising strategy for the inhibition of tumor growth and dissemination. Evidence suggests that tumor ...
Astroglia: Not Just Glue
Journal of Neuropsychiatry (subscription) - May 1, 2008
The study of astroglia is providing insights into existing treatments as well as new avenues to explore that have great therapeutic potential. ...
PharmaGap reports positive early results for next drug compound
Canada NewsWire (press release), Canada - Apr 24, 2008
About PharmaGap Inc. PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic ...CVE:GAP
Alcoholic Lung Disease
RedOrbit, TX - Apr 30, 2008
At the same time, novel therapeutic targets could be utilized in treating these uniquely vulnerable people. However, there have been no systems biological ...
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug ...
Psychosomatics (subscription) - Apr 30, 2008
8 More recently, it has become clear that the concept of the therapeutic window is necessary in understanding how CYP polymorphic variation may influence ...
Peptide Amphiphile Molecules for Rebuilding Nerves after Spinal ...
Medi News Direct, India - Apr 20, 2008
Several researchers are conducting further tests to evaluate the therapeutic outcome of this technique and the initial results of these studies were ...
Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model
Earthtimes, UK - Apr 8, 2008
The protection we see in these mouse models suggests that pharmacologic blockade of Syk with R788 may provide a good therapeutic strategy to treat and ...RIGL
Source: Google News

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic -
CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, … - Cancer Cell, 2004 - Elsevier
... to multiple conventional and novel anti-MM ... evaluate whether IGF-1R inhibition can
enhance ... antitumor activity of existing therapeutic strategies, eg, cytotoxic ...

Novel therapeutic approaches for multiple myeloma. -
T Hideshima, P Richardson, KC Anderson - Immunological Reviews, 2003 - pt.wkhealth.com
... rationale for using a proteasome inhibitor in MM ... PS-341 is a novel therapeutic agent
to ... the molecular rationale for combination strategies with conventional or ...

Vascular Proliferation and Atherosclerosis: New Perspectives and Therapeutic Strategies -
R Ross - Nat Med, 2002 - medscape.com
... Y. & Sueishi, K. Wild-type p53 gene transfer: a novel therapeutic strategy for
neointimal ... in vascular smooth muscle cells by p27KIP1, an inhibitor of neointima ...

Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer -
SV Rajkumar, PG Richardson, T Hideshima, KC … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... making proteasome inhibition a novel therapeutic target in ... These consequences of
proteasome inhibition have been well ... of this new therapeutic strategy in MM, 68 ...

… Calcium-Release Channel (Ryanodine Receptor) as a Novel Therapeutic Strategy Against Heart Failure -
M Yano, S Kobayashi, M Kohno, M Doi, T Tokuhisa, S … - Circulation, 2003 - Am Heart Assoc
... Mediated Stabilization of Calcium-Release Channel (Ryanodine Receptor) as a Novel
Therapeutic Strategy Against Heart ... PKI indicates protein kinase A inhibitor. ...

Inhibition of p38 MAP kinase as a therapeutic strategy -
JC Lee, S Kumar, DE Griswold, DC Underwood, BJ … - Immunopharmacology, 2000 - Elsevier
... The multi-prong strategy is illustrated below ... The novel structural classes disclosed
in these patent ... to explore for the discovery of potential therapeutic agents ...

The Wnt pathway, cell-cycle activation and ?-amyloid: novel therapeutic strategies in Alzheimer's … -
A Caricasole, A Copani, A Caruso, F Caraci, L … - Trends in Pharmacological Sciences, 2003 - Elsevier
... rescue Wnt activity could provide novel AD therapeutics ... Another possible strategy
is to increase the local ... Wnt activity are promising therapeutic approaches for ...

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease -
DI Dominguez, BD Strooper - Trends in Pharmacological Sciences, 2002 - Elsevier
... Lowering A? production: the secretases as therapeutic targets. ... To advance strategies
that target ?-secretase processing ... is now raised that novel therapies act ...

15-Lipoxygenase and its inhibition: a novel therapeutic target for vascular disease. -
JA Cornicelli, BK Trivedi - Curr Pharm Des, 1999 - ncbi.nlm.nih.gov
... A novel, potent, specific inhibitor of 15-LO that lacks ... a strong scientific rationale
for exploring the inhibition of 15-LO as a therapeutic strategy. ...

Pathophysiological Mechanisms in Osteoarthritis Lead to Novel Therapeutic Strategies -
CJ Malemud, N Islam, TM Haqqi - Cells Tissues Organs, 2003 - content.karger.com
... for developing experimental therapeutic strategies for treating ... hyperplasia caused
by inhibition of apoptosis plays ... suggested that novel strategies employed to ...

Source: Google Scholar

Inhibition Of A Chemical In The Brain Could Result In A Novel Therapeutic Strategy For Obesity

A fat-derived protein known for its effects on the liver and skeletal muscle might also serve as an energy-conserving signal to the brain during periods of starvation, suggests a new study in the July issue of Cell Metabolism, a publication of Cell Press. The substance, known as adiponectin, acts on the brain to boost appetite and slow energy expenditure in an effort to maintain adequate fat stores during lean times, the researchers report.

"Energy homeostasis may be mediated by both short-term regulators, such as gut hormones, and long-term regulators," said Takashi Kadowaki of the University of Tokyo. "In this study, we identified, for the first time, a potential long-term regulator that allows energy to be stored efficiently, namely, adiponectin." The findings offer critical insight into adiponectin's influence over the central nervous system and suggest that selective inhibition of the chemical in the brain may represent a novel therapeutic strategy for obesity and obesity-linked diseases, he added.
White adipose tissue (WAT) is a major site of energy storage and plays an important role in energy balance, the researchers said. It is also recognized as an important endocrine organ that secretes a number of biologically active signaling proteins, called adipokines. Adiponectin, an adipokine secreted exclusively by WAT, is present at relatively high concentrations in the circulation and has been shown to increase the body's response to insulin. Studies have also suggested that decreased circulating levels of adiponectin in obesity and type 2 diabetes may contribute to the insulin resistance that characterizes both conditions.

In addition to its peripheral actions on the liver and skeletal muscle, adiponectin has also been reported to have central actions, Kadowaki said. Recently, however, it was reported that adiponectin is undetectable in human cerebrospinal fluid and does not cross the blood-brain barrier, leaving some doubt about its physiological role in the central nervous system, he added.

The researchers now report evidence in mice that adiponectin receptors are present in the hypothalamic region of the brain and that some forms of the chemical enter the cerebrospinal fluid from the blood. Once in the brain, adiponectin enhances the activity of a metabolic enzyme called AMP-activated protein kinase (AMPK) to stimulate greater food consumption. Moreover, the researchers found that adiponectin decreased energy expenditure. They also showed that blood and spinal fluid adiponectin levels in the brain normally increase during fasting and decrease after refeeding, suggesting that adiponectin acts mainly during food shortages.

In adiponectin-deficient mice, AMPK activity in the brain slowed, causing the animals to eat less and expend more energy. That action, in turn, made the animals resistant to becoming obese even on a high-fat diet. Moreover, animals lacking adiponectin lost more fat after 12 hours of fasting than normal mice did.

Blood levels of another fat hormone, leptin, are regulated inversely in relation to serum adiponectin levels, the researchers noted.

"Thus, central adiponectin/leptin signals may represent the physiological pathway by which hypothalamic AMPK activity and food intake are stimulated during fasting and suppressed after refeeding," they said. "In addition to this short-term regulation of food intake and energy expenditure by adiponectin and leptin, these two adipokines may also participate in the long-term regulation of energy homeostasis. The fundamental roles of leptin and adiponectin seem to be to preserve an adequate fat reserve: leptin acts as a satiety signal, and adiponectin acts as a starvation signal."
The researchers include Naoto Kubota, Iseki Takamoto, and Takashi Kadowaki of the University of Tokyo, CREST, Japan Science and Technology Corporation, and the National Institute of Health and Nutrition in Tokyo, Japan; Wataru Yano, Shinsuke Itoh, Hiroki Kumagai, Hideki Kozono, Hidemi Satoh, Atsushi Tsuchida, Ryozo Nagai, and Kohjiro Ueki of the University of Tokyo in Tokyo, Japan; Tetsuya Kubota of the University of Tokyo, National Institute of Health and Nutrition, and Toho University, Ohashi Hospital in Tokyo, Japan; Toshimasa Yamauchi, Ryo Suzuki, Kazuyuki Tobe of the University of Tokyo, CREST, and Japan Science and Technology Corporation in Tokyo, Japan; Shiki Okamoto, Tetsuya Shiuchi, and Yasuhiko Minokoshi of National Institute for Physiological Sciences in Okazaki, Japan; Masao Moroi and Kaoru Sugi of Toho University, Ohashi Hospital in Tokyo, Japan; Tetsuo Noda of the Japanese Foundation for Cancer Research and Tohoku University School of Medicine in Miyagi, Japan; Hiroyuki Ebinuma of Diagnostics Research Laboratories, Daiichi Pure Chemicals in Ibaraki, Japan; Yoichi Ueta of University of Occupational and Environmental Health in Fukuoka, Japan; Tatsuya Kondo and Eiichi Araki of Kumamoto University in Kumamoto, Japan; Osamu Ezaki of National Institute of Health and Nutrition in Tokyo, Japan; Yasuo Terauchi of Yokohama City University School of Medicine in Kanagawa, Japan.

This work was supported by a Grant-in-Aid for Creative Scientific Research from the Japan Society for the Promotion of Science (10NP0201), a grant from the Juvenile Diabetes Foundation International (1-2003-746), a Grant-in-Aid for the Development of Innovative Technology from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Health Science Research grants (Research on Human Genome and Gene Therapy) from the Ministry of Health and Welfare, a grant for Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research (to T. Kadowaki), a grant for Life & Socio-Medical Sciences from the Kanae Foundation, a grant from the Sankyo Foundation of Life Science, and a grant from Astellas Foundation for Research on Metabolic Disorders (to N.K.).

Kubota et al.: "Adiponectin Stimulates AMP-Activated Protein Kinase in the Hypothalamus and Increases Food Intake." Publishing in Cell Metabolism 6, 55-68, July 2007 DOI 10.1016/j.cmet.2007.06.003 http://www.cellmetabolism.org/

Source: Erin Doonan
Cell Press
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.